Quest Diagnostics Incorporated (LON:0KSX)
Market Cap | 14.76B |
Revenue (ttm) | 7.68B |
Net Income (ttm) | 689.76M |
Shares Out | n/a |
EPS (ttm) | 6.09 |
PE Ratio | 21.40 |
Forward PE | 17.59 |
Dividend | 2.40 (1.33%) |
Ex-Dividend Date | Jul 7, 2025 |
Volume | 5 |
Average Volume | 444 |
Open | 181.63 |
Previous Close | 181.12 |
Day's Range | 180.40 - 181.63 |
52-Week Range | 146.57 - 185.53 |
Beta | 0.54 |
RSI | 53.28 |
Earnings Date | Oct 22, 2025 |
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,... [Read more]
Financial Performance
In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.
Financial numbers in USD Financial StatementsNews

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J. , Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general...

Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND RAPID...

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) ha...

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
SECAUCUS, N.J. , Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will spea...
Quest Diagnostics declares $0.80 dividend

Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividen...
What Does the Market Think About Quest Diagnostics?
Quest Diagnostics's (NYSE: DGX) short percent of float has risen 3.64% since its last report. The company recently reported that it has 4.74 million shares sold short , which is 4.84% of all regular ...

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
SECAUCUS, N.J. and BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at...

Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
SECAUCUS, N.J. , Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisiti...

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology busi...

ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery
Clinical research organization ICON plc (NASDAQ: ICLR) stock is surging on Thursday after the company reported better-than-expected second-quarter financial results and raised its fiscal 2025 sales g...

Quest Diagnostics Boosts Its 2025 Outlook

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
Quest Diagnostics Inc. DGX delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.
Quest Diagnostics Incorporated 2025 Q2 - Results - Earnings Call Presentation
Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript
Quest Diagnostics rises on upbeat results, guidance raise

Quest Diagnostics raises annual forecasts on strong diagnostic testing demand
Laboratory operator Quest Diagnostics raised its 2025 profit and revenue forecasts on Tuesday, banking on robust demand for its diagnostic tests, sending the company's shares up over 3% in premarket t...

Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2...
Quest Diagnostics Q2 2025 Earnings Preview

Quest Diagnostics Earnings Preview
Quest Diagnostics (NYSE: DGX) is gearing up to announce its quarterly earnings on Tuesday, 2025-07-22. Here's a quick overview of what investors should know before the release. Analysts are estimatin...

Quest Diagnostics Introduces Testing for Oropouche Virus
Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J. , July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic info...
Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today
Quest Diagnostics to offer Fujirebio Alzheimer's diagnostic test

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July 9...